On October 22, 2009, Acorda Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration (FDA) has extended the PDUFA goal date for its review of the New Drug Application (NDA) for Fampridine-SR to January 22, 2010.
Item 9.01 Financial Statements and Exhibits
99.1 Press Release dated October 22, 2009.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Acorda Therapeutics, Inc. |
||
|
|
|
|
|
|
October 22, 2009 |
By: |
/s/ David Lawrence |
|
|
|
|
Name: |
David Lawrence |
|
|
|
Title: |
Chief Financial Officer |
Exhibit Index
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release dated October 22, 2009. |